FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1217-1222 October 26, 2000 Number 17 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non–small-cell lung cancer.

Methods After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per square meter of body-surface area intravenously on day 1) and etoposide (120 mg per square meter intravenously on days 1, 2, and 3) administered concurrently with radiotherapy (a total of 50.4 Gy, given in 28 daily fractions) or radiotherapy alone (a total of 50.4 Gy, given in 28 daily fractions).

Results Of the 488 patients who were enrolled in the study, 242 were assigned to receive radiotherapy alone and 246 were assigned to receive chemotherapy and radiotherapy. The median duration of follow-up was 44 months. Treatment-associated mortality was 1.2 percent in the group given radiotherapy alone and 1.6 percent in the group given chemotherapy and radiotherapy. The median survival was 39 months in the group given radiotherapy and 38 months in the group given chemotherapy and radiotherapy (P= 0.56 by the log-rank test). The relative likelihood of survival among patients assigned to receive chemotherapy and radiotherapy, as compared with those assigned to receive radiotherapy alone, was 0.93 (95 percent confidence interval, 0.74 to 1.18). Intrathoracic disease recurred within the radiation field in 30 of 234 patients (13 percent) in the group given radiotherapy and in 28 of 236 patients (12 percent) in the group given chemotherapy and radiotherapy (P=0.84); data on recurrence were not available for 18 patients.

Conclusions As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non–small-cell lung cancer.

Source Information

From the Department of Surgery, Beth Israel Medical Center, New York (S.M.K.); the Department of Biostatistics, Dana–Farber Cancer Institute, Boston (S.A.); the Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Fla. (H.W.); the Department of Radiation Oncology, Oakwood Hospital, Detroit (A.H.); the Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston (R.K.); the Division of Medical Oncology, Ochsner Clinic, Baton Rouge, La. (B.J.B.); the Division of Hematology and Medical Oncology, University of Missouri, Ellis Fischer Cancer Center, Columbia (M.C.P.); the Division of Medical Oncology, University of Washington, Seattle (R.B.L.); and the Division of Medical Oncology, Vanderbilt University, Nashville (D.H.J.).

Address reprint requests to Dr. Keller at the Department of Surgery, Beth Israel Medical Center, First Ave. and 16th St., New York, NY 10003, or at skeller{at}bethisraelny.org.

Full Text of this Article

This article has been cited by other articles:

• Schettino, C., Bareschino, M. A., Rossi, A., Maione, P., Castaldo, V., Mazzeo, N., Sacco, P. C., Ferrara, M. L., Palazzolo, G., Ciardiello, F., Gridelli, C. (2009). Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology 1: 5-13 [Abstract]  
• Chhatwani, L., Cabebe, E., Wakelee, H. A. (2009). Adjuvant Treatment of Resected Lung Cancer. Proc Am Thorac Soc 6: 194-200 [Abstract] [Full Text]  
• Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., Spiro, S. G., Rolland, E., Fossati, R., Aubert, D., Ding, K., Waller, D., Le Chevalier, T. (2008). Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. JCO 26: 3552-3559 [Abstract] [Full Text]  
• Ost, D., Goldberg, J., Rolnitzky, L., Rom, W. N. (2008). Survival after Surgery in Stage IA and IB Non-Small Cell Lung Cancer. Am. J. Respir. Crit. Care Med. 177: 516-523 [Abstract] [Full Text]  
• Pisters, K. M.W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., Gaspar, L. E., Pass, H. I., Spigel, D. R., Strawn, J. R., Ung, Y. C., Shepherd, F. A. (2007). Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline. JCO 25: 5506-5518 [Abstract] [Full Text]  
• Whitson, B. A., Groth, S. S., Maddaus, M. A. (2007). Surgical Assessment and Intraoperative Management of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer. Ann. Thorac. Surg. 84: 1059-1065 [Abstract] [Full Text]  
• Robinson, L. A., Ruckdeschel, J. C., Wagner, H. Jr, Stevens, C. W. (2007). Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 243S-265S [Abstract] [Full Text]  
• Ng, R., Hasan, B., Mittmann, N., Florescu, M., Shepherd, F. A., Ding, K., Butts, C. A., Cormier, Y., Darling, G., Goss, G. D., Inculet, R., Seymour, L., Winton, T. L., Evans, W. K., Leighl, N. B. (2007). Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer--A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. JCO 25: 2256-2261 [Abstract] [Full Text]  
• Dubey, S., Powell, C. A. (2007). Update in Lung Cancer 2006. Am. J. Respir. Crit. Care Med. 175: 868-874 [Full Text]  
• Wakelee, H., Dubey, S., Gandara, D. (2007). Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer--How to Handle Stage I Disease. The Oncologist 12: 331-337 [Abstract] [Full Text]  
• Turrisi, A., Keller, S. (2007). Since Chemotherapy Is Now the Standard in Node-Positive Lung Cancer, What Is the Role of Postoperative Radiotherapy?. JCO 25: 459-460 [Full Text]  
• Araujo, A., Ribeiro, R., Azevedo, I., Coelho, A., Soares, M., Sousa, B., Pinto, D., Lopes, C., Medeiros, R., Scagliotti, G. V. (2007). Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature. The Oncologist 12: 201-210 [Abstract] [Full Text]  
• Hanna, N. H., Einhorn, L. H. (2006). Postoperative Chemotherapy for N2 Non Small-Cell Lung Cancer: Conclusions Are Not Black and White, but Gray. JCO 24: 5611-5612 [Full Text]  
• West, D., Kirk, A. J.B., Dunning, J. (2006). Chemotherapy following complete resection of non-small-cell lung cancer is of small but significant benefit in terms of survival. ICVTS 5: 488-492 [Abstract] [Full Text]  
• Lally, B. E., Zelterman, D., Colasanto, J. M., Haffty, B. G., Detterbeck, F. C., Wilson, L. D. (2006). Postoperative Radiotherapy for Stage II or III Non-Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. JCO 24: 2998-3006 [Abstract] [Full Text]  
• Bonner, J. A., Spencer, S. A. (2006). Postoperative Radiotherapy in Non--Small-Cell Lung Cancer Warrants Further Exploration in the Era of Adjuvant Chemotherapy and Conformal Radiotherapy. JCO 24: 2978-2980 [Full Text]  
• Alam, N., Darling, G., Shepherd, F. A., Mackay, J. A., Evans, W. K., Lung Cancer Disease Site Group of Cancer Care Onta, (2006). Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review.. Ann. Thorac. Surg. 81: 1926-1936 [Abstract] [Full Text]  
• Meyers, B. F., Haddad, F., Siegel, B. A., Zoole, J. B., Battafarano, R. J., Veeramachaneni, N., Cooper, J. D., Patterson, G. A. (2006). Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J. Thorac. Cardiovasc. Surg. 131: 822-829 [Abstract] [Full Text]  
• d'Amato, T. A., Landreneau, R. J., McKenna, R. J., Santos, R. S., Parker, R. J. (2006). Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Nonsmall-Cell Lung Cancer. Ann. Thorac. Surg. 81: 440-447 [Abstract] [Full Text]  
• Martin, L. W., Correa, A. M., Hofstetter, W., Hong, W. K., Komaki, R., Putnam, J. B. Jr, Rice, D. C., Smythe, W. R., Swisher, S. G., Vaporciyan, A. A., Walsh, G. L., Roth, J. A. (2005). The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J. Thorac. Cardiovasc. Surg. 130: 1601-1610 [Abstract] [Full Text]  
• Visbal, A. L., Leighl, N. B., Feld, R., Shepherd, F. A. (2005). Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest 128: 2933-2943 [Abstract] [Full Text]  
• Green, M. R., Andrews, M., Leff, R., Willey, J., Allegra, C., Denes, A., Epstein, J., Jones, J., Lokey, L. (2005). Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data. J Oncol Pract 1: 37-42 [Abstract] [Full Text]  
• Bogart, J. A., Aronowitz, J. N. (2005). Localized Non-Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy. Clin. Cancer Res. 11: 5004s-5010s [Abstract] [Full Text]  
• Johnson, B. E., Rabin, M. S. (2005). Patient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non-Small Cell Lung Cancer. Clin. Cancer Res. 11: 5022s-5026s [Abstract] [Full Text]  
• Thatcher, N., Faivre-Finn, C., Blackhall, F., Anderson, H., Lorigan, P. (2005). Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. Clin. Cancer Res. 11: 5051s-5056s [Abstract] [Full Text]  
• Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., Fry, W., Bethune, D., Ayoub, J., Ding, K., Seymour, L., Graham, B., Tsao, M.-S., Gandara, D., Kesler, K., Demmy, T., Shepherd, F., the National Cancer Institute of Canada Clinical T, (2005). Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. NEJM 352: 2589-2597 [Abstract] [Full Text]  
• Pisters, K. M.W. (2005). Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer -- The Smoke Clears. NEJM 352: 2640-2642 [Full Text]  
• Bradley, J. D., Paulus, R., Graham, M. V., Ettinger, D. S., Johnstone, D. W., Pilepich, M. V., Machtay, M., Komaki, R., Atkins, J., Curran, W. J. (2005). Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small-Cell Lung Cancer: Promising Long-Term Results of the Radiation Therapy Oncology Group--RTOG 9705. JCO 23: 3480-3487 [Abstract] [Full Text]  
• Pisters, K. M.W., Le Chevalier, T. (2005). Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer. JCO 23: 3270-3278 [Abstract] [Full Text]  
• Mamon, H. J., Yeap, B. Y., Janne, P. A., Reblando, J., Shrager, S., Jaklitsch, M. T., Mentzer, S., Lukanich, J. M., Sugarbaker, D. J., Baldini, E. H., Berman, S., Skarin, A., Bueno, R. (2005). High Risk of Brain Metastases in Surgically Staged IIIA Non-Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation. JCO 23: 1530-1537 [Abstract] [Full Text]  
• Nakagawa, M., Tanaka, F., Tsubota, N., Ohta, M., Takao, M., Wada, H., On behalf of the West Japan Study Group for Lung C, (2005). A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. Ann Oncol 16: 75-80 [Abstract] [Full Text]  
• Okubo, K., Kato, T., Hara, A., Yoshimi, N., Takeda, K., Iwao, F. (2004). Imprint Cytology for Detecting Metastasis of Lung Cancer in Mediastinal Lymph Nodes. Ann. Thorac. Surg. 78: 1190-1193 [Abstract] [Full Text]  
• Lynch, T. J., Wright, C. D., Choi, N. C., Aquino, S. L., Mark, E. J. (2004). Case 26-2004 - A 56-Year-Old Woman with Cough and a Lung Nodule. NEJM 351: 809-817 [Full Text]  
• Waller, D., Peake, M.D., Stephens, R.J., Gower, N.H., Milroy, R., Parmar, M.K.B., Rudd, R.M., Spiro, S.G. (2004). Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 26: 173-182 [Abstract] [Full Text]  
• Keller, S. M., Vangel, M. G., Wagner, H., Schiller, J. H., Herskovic, A., Komaki, R., Marks, R. S., Perry, M. C., Livingston, R. B., Johnson, D. H. (2004). Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J. Thorac. Cardiovasc. Surg. 128: 130-137 [Abstract] [Full Text]  
• Trodella, L., Granone, P., Valente, S., Margaritora, S., Macis, G., Cesario, A., D'Angelillo, R. M., Valentini, V., Corbo, G. M., Porziella, V., Ramella, S., Tonini, G., Galetta, D., Ciresa, M., Vincenzi, B., Cellini, N. (2004). Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 15: 389-398 [Abstract] [Full Text]  
• The International Adjuvant Lung Cancer Trial Colla, (2004). Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. NEJM 350: 351-360 [Abstract] [Full Text]  
• Spira, A., Ettinger, D. S. (2004). Multidisciplinary Management of Lung Cancer. NEJM 350: 379-392 [Full Text]  
• Hsu, H-C, Wang, C-J, Huang, E-Y, Sun, L-M (2004). Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors. Br. J. Radiol. 77: 43-48 [Abstract] [Full Text]  
• Vlahovic, G., Crawford, J. (2003). Activation of Tyrosine Kinases in Cancer. The Oncologist 8: 531-538 [Abstract] [Full Text]  
• Johnson, B. E. (2003). Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: The End of the Beginning. JNCI J Natl Cancer Inst 95: 1422-1424 [Full Text]  
• Scagliotti, G. V., Fossati, R., Torri, V., Crino, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F., Tonato, M. (2003). Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. JNCI J Natl Cancer Inst 95: 1453-1461 [Abstract] [Full Text]  
• Nagai, K., Tsuchiya, R., Mori, T., Tada, H., Ichinose, Y., Koike, T., Kato, H. (2003). A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J. Thorac. Cardiovasc. Surg. 125: 254-260 [Abstract] [Full Text]  
• Scott, W. J., Howington, J., Movsas, B. (2003). Treatment of Stage II Non-small Cell Lung Cancer. Chest 123: 188S-201S [Abstract] [Full Text]  
• Spiro, S. G., Porter, J. C. (2002). Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment. Am. J. Respir. Crit. Care Med. 166: 1166-1196 [Abstract] [Full Text]  
• Martin, J., Ginsberg, R. J., Venkatraman, E. S., Bains, M. S., Downey, R. J., Korst, R. J., Kris, M. G., Rusch, V. W. (2002). Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer. JCO 20: 1989-1995 [Abstract] [Full Text]  
• Vallieres, E., Machtay, M., Glatstein, E., Bonner, J. A. (2002). Adjuvant Radiation Therapy After Complete Resection of Non-Small-Cell Lung Cancer. JCO 20: 1427-1429 [Full Text]  
• Bach, P. B., Cramer, L. D., Schrag, D., Downey, R. J., Gelfand, S. E., Begg, C. B. (2001). The Influence of Hospital Volume on Survival after Resection for Lung Cancer. NEJM 345: 181-188 [Abstract] [Full Text]  
• Cortes, J., Rodriguez, J., Calvo, E., Greco, F. A., Shigemitsu, H., Kuschner, W. G., Keller, S. M., Johnson, D. H. (2001). Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer. NEJM 344: 689-690 [Full Text]  
• Edelman, M. J. (2001). New Directions in the Treatment of Non-Small Cell Lung Cancer: An Overview. The Oncologist 6: 1-3 [Abstract] [Full Text]  
• (2000). Chemotherapy Ineffective for Locally Advanced Lung Cancer. JWatch General 2000: 4-4 [Full Text]  
• Carney, D. N., Hansen, H. H. (2000). Non-Small-Cell Lung Cancer -- Stalemate or Progress?. NEJM 343: 1260-1262 [Full Text]